Rigel Pharmaceuticals Management
Management criteria checks 2/4
Rigel Pharmaceuticals' CEO is Raul Rodriguez, appointed in May 2010, has a tenure of 9.5 years. total yearly compensation is $3.44M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth €1.19M. The average tenure of the management team and the board of directors is 3 years and 6.6 years respectively.
Key information
Raul Rodriguez
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 21.2% |
| CEO tenure | 14yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$3m | US$728k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$3m | US$700k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$3m | US$662k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$3m | US$662k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$3m | US$649k | -US$67m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$64m |
| Dec 31 2018 | US$4m | US$637k | -US$70m |
| Sep 30 2018 | n/a | n/a | -US$100m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$87m |
| Dec 31 2017 | US$2m | US$618k | -US$78m |
Compensation vs Market: Raul's total compensation ($USD3.44M) is above average for companies of similar size in the German market ($USD713.59K).
Compensation vs Earnings: Raul's compensation has increased whilst the company is unprofitable.
CEO
Raul Rodriguez (62 yo)
14yrs
Tenure
US$3,440,790
Compensation
Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 14yrs | US$3.44m | 0.75% $ 1.2m | |
| Executive VP & CFO | 6yrs | US$1.21m | 0.069% $ 110.4k | |
| Executive VP | 1.4yrs | US$683.00k | 0.0029% $ 4.5k | |
| Executive VP & Chief Commercial Officer | 3.8yrs | US$1.34m | 0.031% $ 50.0k | |
| Senior VP of Human Resources | 2.3yrs | no data | no data | |
| Executive Vice President of Research | 7.7yrs | US$796.09k | no data | |
| Executive VP & Chief Business Officer | less than a year | no data | no data | |
| Executive VP & Chief Medical Officer | less than a year | no data | no data | |
| Vice President of Marketing | no data | no data | no data |
3.0yrs
Average Tenure
60yo
Average Age
Experienced Management: RI2A's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.5yrs | US$3.44m | 0.75% $ 1.2m | |
| Independent Director | 18.6yrs | US$113.58k | 0.029% $ 45.4k | |
| Independent Director | 27.2yrs | US$138.58k | 0.030% $ 47.4k | |
| Independent Director | 6.8yrs | US$138.58k | 0.029% $ 45.4k | |
| Independent Director | 5.2yrs | US$145.58k | 0.029% $ 45.4k | |
| Independent Chairman of the Board | 6.5yrs | US$190.58k | 0.029% $ 45.4k | |
| Independent Director | 2.4yrs | US$140.58k | 0.011% $ 17.0k | |
| Independent Director | 3yrs | US$212.98k | 0.018% $ 28.4k |
6.6yrs
Average Tenure
65.5yo
Average Age
Experienced Board: RI2A's board of directors are considered experienced (6.6 years average tenure).